Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions

J Alexander, E Cukierman - Current opinion in cell biology, 2016 - Elsevier
Highlights•Innate mesenchymal-stroma maintains a tumor-suppressive homeostatic
equilibrium.•Fibroblastic-ECM interplay is referred to as stromal dynamic reciprocity.• …

Chemoresistance in pancreatic cancer: Emerging concepts

M Gnanamony, CS Gondi - Oncology letters, 2017 - spandidos-publications.com
Pancreatic cancer is one of the most lethal types of cancer in the world. The incidence of
pancreatic cancer increases each year with no significant decrease in mortality. Pancreatic …

Pancreatic cancer (PDAC): introduction of evidence-based complementary measures into integrative clinical management

V Jentzsch, J Davis, MBA Djamgoz - Cancers, 2020 - mdpi.com
Simple Summary Pancreatic ductal adenocarcinoma is a devastating disease that is very
hard to treat. Here, we advance and evaluate the notion that the best possible management …

The interplay of the extracellular matrix and stromal cells as a drug target in stroma-rich cancers

N Kozlova, JE Grossman, MP Iwanicki… - Trends in pharmacological …, 2020 - cell.com
The tumor microenvironment (TME) is a complex neighborhood that consists of immune
cells, fibroblasts, pericytes, adipocytes, endothelial and neuronal cells, and the extracellular …

Vitamin D and pancreatic cancer

SG Barreto, RE Neale - Cancer letters, 2015 - Elsevier
Pancreatic cancer is currently the fourth leading cause of cancer-related death, and it is
projected that within the next two decades it will become the second most common cause of …

Concise review: stem cells in pancreatic cancer: from concept to translation

D Raj, A Aicher, C Heeschen - Stem cells, 2015 - academic.oup.com
Pancreatic cancer stem cells (CSCs) have been first described in 2007 and since then have
emerged as an intriguing entity of cancer cells with distinct functional features including self …

Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to …

RC Ramaker, AA Hardigan, ER Gordon, CA Wright… - BMC cancer, 2021 - Springer
Background Pancreatic ductal adenocarcinoma (PDAC) patients suffer poor outcomes,
including a five-year survival of below 10%. Poor outcomes result in part from therapeutic …

Insight into the roles of vitamins C and D against cancer: myth or truth?

CN Zhao, Y Li, X Meng, S Li, Q Liu, GY Tang, RY Gan… - Cancer letters, 2018 - Elsevier
The consumption of vitamins C and D for prevention and treatment of cancer is still an
uncertain recommendation due to their controversial roles in cancer. The epidemiological …

K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?

R Nussinov, S Muratcioglu, CJ Tsai… - Expert Opinion on …, 2016 - Taylor & Francis
Introduction: Decades of efforts have yet to yield a safe and effective drug to target KRAS-
driven pancreatic, colorectal and lung cancers; particularly those driven by the highly …

Effects of 1,25(OH)2D3 on Cancer Cells and Potential Applications in Combination with Established and Putative Anti-Cancer Agents

MA Abu el Maaty, S Wölfl - Nutrients, 2017 - mdpi.com
The diverse effects of 1, 25-dihydroxyvitamin D3 (1, 25 (OH) 2D3), the bio-active form of
vitamin D, on cancer cell metabolism and proliferation has made it an interesting candidate …